Media Database
>
Joshua Cohen

Joshua Cohen

Editor at Boston Review

Contact this person
Email address
j*****@*******.comGet email address
Influence score
23
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Languages
  • English
Covering topics
  • Law
  • Science
  • Politics

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

forbes.com

RFK Jr. Says He Wants To Untie Links Between Industry And FDA

It's unclear to what extent RFK Jr would want to disrupt a drug review process that has given the US a comparative advantage, albeit at the expense of industry dependency
forbes.com

Biden Administration Proposes Covering Obesity Drugs In Medicare An...

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive decisions made by the incoming Trump administration.
forbes.com

How RFK Jr.’s Pledge To Make America Eat Healthier Clashes With Trump

RFK Jr. wants Americans to eat healthier by fixing what he deems is a corrupt food ecosystem. But this flies in the face of actions taken Trump during his first term.
forbes.com

Harris’ Healthcare Plans And Trump’s Concepts Of A Plan: Implicatio...

Stark differences in policy have emerged between the campaigns of Harris and Trump that would impact patient’s access to healthcare.
forbes.com

Democrats Blumenthal And Tonko Introduce New Bill To Curb Gambling ...

Representative Tonko and Senator Blumenthal aim to limit possibly harmful ad practices and offer federal help to investigate problem gambling and treat sufferers.
forbes.com

U.S. Healthcare System Ranks Last Among 10 Nations, According To Ne...

Among ten peer nations, Americans live the shortest lives and are the least healthy, despite the U.S. spending the most on healthcare, according to a new study.
forbes.com

Ozempic Shortages Raise Questions About Prioritizing Access For Dia...

Because of shortages of GLP-1 medicines, Type 2 diabetics sometimes can’t get them. This raises questions about prioritizing access to these drugs for diabetes patients.